nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

05.10.2019 | Original Article – Clinical Oncology

“Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”

verfasst von: Neval E. Wareham, Qiuju Li, Henrik Sengeløv, Caspar Da Cunha-Bang, Finn Gustafsson, Carsten Heilmann, Michael Perch, Allan Rasmussen, Søren Schwartz Sørensen, Amanda Mocroft, Jens D. Lundgren

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Solid organ (SOT) and allogeneic haematopoietic stem cell (HSCT) transplant recipients have elevated risks of de novo or secondary cancer. We explored risk factors hereof.

Methods

Among SOT and HSCT between January 2004 and December 2014, standardised incidence ratio (SIR) of de novo/secondary cancer compared with the Danish population was determined and risk factors were identified using Poisson regression.

Results

During a median of 3.4 (IQR 1.3–6.4) and 2.6 (0.8–5.4) person-years (PY) after SOT and HSCT, a total of 212/1656 (13%) and 75/992 (8%) persons developed cancer; SIR 3.61 (3.0–4.3) and 2.2 (1.6–3.0), resp.). SIR correlated with younger age and was highest for skin and haematological cancers for both types of transplantation. Within the cohort, cancer was associated with older age (adjusted incidence rate ratio > 50 vs ≤ 19 years, among SOT and HSCT: 9.4 (3.4–25.7) and 25.4 (5.1–126.0), resp.) and current elevated C-reactive protein (CRP) (≥ 10 vs < 10 mg/L: 2.5 (1.8–3.4) and 2.3 (1.4–3.9), resp.), but neither with prior cancer nor type of immunosuppressants.

Conclusion

Rates of de novo or secondary cancers are elevated in both SOT and HSCT compared with the general population and mainly for skin and haematological cancers. Among transplant recipients, older age and current elevated CRP are risk factors.

Aagaard T, Reekie J, Roen A, Daugaard G, Specht L, Sengelov H et al (2019) Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: the (CSR) FENCE score. Int J Cancer. https://doi.org/10.1002/ijc.32249 CrossRefPubMed

Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B et al (2003) Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 89(7):1221–1227PubMedPubMedCentral

Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27(13):2217–2224PubMed

Allin KH, Bojesen SE, Nordestgaard BG (2016) Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population. Int J Cancer 139(7):1493–1500PubMed

Billups K, Neal J, Salyer J (2015) Immunosuppressant-driven de novo malignant neoplasms after solid-organ transplant. Prog Transplant 25(2):182–188PubMed

Borges AH, Neuhaus J, Sharma S, Neaton JD, Henry K, Anagnostou O et al (2019) The effect of interrupted/deferred antiretroviral therapy on disease risk: a smart and start combined analysis. J Infect Dis 219(2):254–263PubMed

Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ 82:1–406

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMed

Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR et al (2010) C-reactive protein and risk of lung cancer. J Clin Oncol 28(16):2719–2726PubMedPubMedCentral

Chien SH, Liu CJ, Hong YC, Teng CJ, Hu YW, Shen CC et al (2015) Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study. Br J Cancer 112(1):177–184PubMed

Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madeleine MM (2016) Immunosuppressive Medications and Squamous Cell Skin Carcinoma: nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. Am J Transplant 16(2):565–573PubMedPubMedCentral

Collett D, Mumford L, Banner NR, Neuberger J, Watson C (2010) Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 10(8):1889–1896PubMed

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081PubMed

Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336(13):897–904PubMed

Ekenberg C, Lodding IP, Wareham NE, Sorensen SS, Sengelov H, Gustafsson F et al (2017) Risk of infectious diseases among first-degree relatives of transplant recipients who develop CMV infection: is the infectious phenotype inheritable? Eur J Clin Microbiol Infect Dis 36(12):2391–2398PubMed

Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ et al (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306(17):1891–1901PubMedPubMedCentral

Frydenberg H, Thune I, Lofterod T, Mortensen ES, Eggen AE, Risberg T et al (2016) Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat 155(2):345–354PubMed

Ghuman S, Van HM, Garmo H, Holmberg L, Malmstrom H, Lambe M et al (2017) Serum inflammatory markers and colorectal cancer risk and survival. Br J Cancer 116(10):1358–1365PubMedPubMedCentral

Grulich AE, Vajdic CM (2015) The epidemiology of cancers in human immunodeficiency virus infection and after organ transplantation. Semin Oncol 42(2):247–257PubMed

Herishanu Y, Polliack A, Shenhar-Tsarfaty S, Weinberger R, Gelman R, Ziv-Baran T et al (2017) Increased serum C-reactive protein levels are associated with shorter survival and development of second cancers in chronic lymphocytic leukemia. Ann Med 49(1):75–82PubMed

Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397(6719):530–534PubMed

Hortlund M, Arroyo Muhr LS, Storm H, Engholm G, Dillner J, Bzhalava D (2017) Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer 140(5):1091–1101PubMed

Ilett EE, Helleberg M, Reekie J, Murray DD, Wulff SM, Khurana MP et al (2019) Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Open Forum Infect Dis 6(4):ofz086PubMedPubMedCentral

Ingvar A, Smedby KE, Lindelof B, Fernberg P, Bellocco R, Tufveson G et al (2010) Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant 25(8):2764–2771PubMed

Izano M, Wei EK, Tai C, Swede H, Gregorich S, Harris TB et al (2016) Chronic inflammation and risk of colorectal and other obesity-related cancers: the health, aging and body composition study. Int J Cancer 138(5):1118–1128PubMed

Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM et al (2011) Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 117(1):316–322PubMedPubMedCentral

Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K et al (2014) Genetic variation across C-reactive protein and risk of prostate cancer. Prostate 74(10):1034–1042PubMedPubMedCentral

Nelson AS, Ashton LJ, Vajdic CM, Le Marsney RE, Daniels B, Nivison-Smith I et al (2015) Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy. Leukemia 29(2):441–447PubMed

Nelson SH, Brasky TM, Patterson RE, Laughlin GA, Kritz-Silverstein D, Edwards BJ et al (2017a) The Association of the C-Reactive Protein Inflammatory Biomarker with Breast Cancer Incidence and Mortality in the Women’s Health Initiative. Cancer Epidemiol Biomarkers Prev 26(7):1100–1106PubMedPubMedCentral

Nelson AS, Vajdic CM, Ashton LJ, Le Marsney RE, Nivison-Smith I, Wilcox L et al (2017b) Incident cancers and late mortality in Australian children treated by allogeneic stem cell transplantation for non-malignant diseases. Pediatr Blood Cancer 64(1):197–202PubMed

Pomerantz MM, Freedman ML (2011) The genetics of cancer risk. Cancer J 17(6):416–422PubMedPubMedCentral

Prizment AE, Anderson KE, Visvanathan K, Folsom AR (2011) Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 20(2):297–307PubMedPubMedCentral

Proby CM, Harwood CA, Neale RE, Green AC, Euvrard S, Naldi L et al (2011) A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 11(7):1498–1508PubMed

Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ (2017) Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390(10105):1833–1842PubMed

Ringden O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D et al (2014) Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant 20(11):1777–1784PubMedPubMedCentral

Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113(5):1175–1183PubMedPubMedCentral

Vajdic CM, Mayson E, Dodds AJ, O’Brien T, Wilcox L, Nivison-Smith I et al (2016) Second Cancer Risk and Late Mortality in Adult Australians Receiving Allogeneic Hematopoietic Stem Cell Transplantation: a Population-Based Cohort Study. Biol Blood Marrow Transplant 22(5):949–956PubMed

van Leeuwen MT, Webster AC, McCredie MR, Stewart JH, McDonald SP, Amin J et al (2010) Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 11(340):c570

Wareham NE, Mocroft A, Sengelov H, da Cunha-Bang C, Gustafsson F, Heilmann C et al (2018a) The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. J Cancer Res Clin Oncol 144:1569–1580PubMed

Wareham NE, Da Cunha-Bang C, Borges AH, Ekenberg C, Gerstoft J, Gustafsson F et al (2018b) Classification of death causes after transplantation (CLASS): evaluation of methodology and initial results. Medicine (Baltimore) 97(29):e11564

Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR (2007) Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 7(9):2140–2151PubMed

Yanik EL, Gustafson SK, Kasiske BL, Israni AK, Snyder JJ, Hess GP et al (2015) Sirolimus use and cancer incidence among US kidney transplant recipients. Am J Transplant 15(1):129–136PubMed

Yuan B, Wang Y (2008) Mutagenic and cytotoxic properties of 6-thioguanine, S6-methylthioguanine, and guanine-S6-sulfonic acid. J Biol Chem 283(35):23665–23670PubMedPubMedCentral

Titel: “Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”
verfasst von: Neval E. Wareham
Qiuju Li
Henrik Sengeløv
Caspar Da Cunha-Bang
Finn Gustafsson
Carsten Heilmann
Michael Perch
Allan Rasmussen
Søren Schwartz Sørensen
Amanda Mocroft
Jens D. Lundgren
Publikationsdatum: 05.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03039-2

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

“Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”